Health Catalyst Inc

Aktienanalyse zu Health Catalyst Inc (HCAT)

$1.500

-0.085 (-5.66%)Zum Schluss

Loading chart…
Hoch
1.590
Eröffnung
1.590
Volumengewichteter Durchschnittskurs
1.51
Volumen
336.35K
Marktkap.
357.16M
Tief
1.450
Umsatz
509.00K
EV/EBITDA, TTM
6.09

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

KI-Analyse of Health Catalyst Inc (HCAT)

Verkaufen

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Health Catalyst Inc (HCAT) beträgt 10.00, verglichen mit dem 5-Jahres-Durchschnitt von -7.88.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
-7.88
Aktuelles P/E
10.00
Überbewertet
103.22
Unterbewertet
-118.99

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-53.03
Aktuelles EV/EBITDA
6.09
Überbewertet
98.36
Unterbewertet
-204.42

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
1.83
Aktuelles P/S
0.58
Überbewertet
3.43
Unterbewertet
0.24

Alphio-AI-Kursszenarien für HCAT

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%HCAT

$4.94

Szenariopreis

B

Basis

Basis · 50%HCAT

$4.25

Szenariopreis

B

Bärisch

Bärisch · 25%HCAT

$4.22

Szenariopreis

Whales, die HCAT halten

F

First Light Asset Management, LLC

+ HältHCAT

+0.00%

3-Monats-Rendite

Event-Zeitleiste

2026-09-08 (ET)

09:00:00

Health Catalyst Appoints Simeon Kohl as CEO

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

News

HCAT FAQ – beantwortet von Alphio AI

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln